Author:
Carli P. M.,Troussard X.,Maarouf N.,Maynadié M.
Reference6 articles.
1. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
2. Sant M, Aareleid T, Berrino F et al. EUROCARE-3: survival of cancer patients diagnosed 1990–94-results and commentary. Ann Oncol. 2003;14Suppl 5:v61–118.
3. Cervantes F, Robertson JE, Rozman C et al. Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group. Br J Haematol. 1994;87:293–300.
4. Baccarani M, Martinelli G, Rosti G et al. Working Party on Chronic Myeloid Leukemia. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukaemia. Blood. 2004;104:4245–51.
5. Guilhot F, Roy L, Guilhot J, Millot F. Interferon therapy in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004,18:585–603.